Drug
Trametinib clinical trials
Also written GSK1120212 and JTP-74057.
- studies test it
- 183
- open now
- 30
- in phase 3
- 9
- first study started
- 2008
Keep track of what changes. Save the trametinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
182 studies that test it; most in 2018 (22); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 8 |
| 2011 | 9 |
| 2012 | 9 |
| 2013 | 17 |
| 2014 | 16 |
| 2015 | 11 |
| 2016 | 9 |
| 2017 | 17 |
| 2018 | 22 |
| 2019 | 9 |
| 2020 | 12 |
| 2021 | 10 |
| 2022 | 3 |
| 2023 | 8 |
| 2024 | 7 |
| 2025 | 8 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 80
- Phase 2
- 107
- Phase 3
- 9
- Phase 4
- 3
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 46
Who runs them
Industry 62 · Other 121
GlaxoSmithKline (30) · Novartis Pharmaceuticals (23) · National Cancer Institute (NCI) (15) · M.D. Anderson Cancer Center (10) · Memorial Sloan Kettering Cancer Center (5) · University of California, San Francisco (5) · Melanoma Institute Australia (3) · Massachusetts General Hospital (3)
Often tested with
Tested in the same studies.
Dabrafenib (62) · Pembrolizumab (10) · Nivolumab (8) · Palbociclib (7) · Everolimus (6) · GSK2141795 (6) · Ribociclib (5) · Olaparib (5)
Studies
Open first, then newest update. How each study uses trametinib is read from its arms, and is right about nine times in ten.
Testing it · 183
- Dabrafenib and/or Trametinib Rollover StudyRecruitingPhase 4Novartis PharmaceuticalsNCT03340506Written as trametinib
- Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasRecruitingPhase 2University of California, San FranciscoNCT07110246Written as Trametinib
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07886905Written as Trametinib
- 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAsRecruitingPhase 2Children's Hospital of PhiladelphiaNCT07549646Written as Trametinib
- Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERITNot yet recruitingPhase 3Carelon ResearchNCT07817186Written as Trametinib
- Pediatric Low Grade Glioma - MEKinhibitor TRIal vs ChemotherapyRecruitingPhase 2University Hospital, Strasbourg, FranceNCT05180825Written as Trametinib
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)RecruitingPhase 1University of California, San FranciscoNCT04485559Written as Trametinib
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT07440290Written as Trametinib
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Trametinib
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaRecruitingPhase 1/2GenfitNCT05874414Written as GNS561 + Trametinib
- MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingPhase 1/2Ann & Robert H Lurie Children's Hospital of ChicagoNCT06712875Written as Trametinib and Nivolumab
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as Trametinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Dabrafenib+Trametinib
- Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibRecruitingPhase 2Cook Children's Health Care SystemNCT06582745Written as Trametinib
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07477457Written as Trametinib
- HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingPhase 1/2Princess Maxima Center for Pediatric OncologyNCT05658640Written as Trametinib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Trametinib
- Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingPhase 1China Medical University HospitalNCT06962254Written as Trametinib
- XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNot yet recruitingPhase 1/2Xynomic Pharmaceuticals, Inc.NCT05275374Written as Trametinib
- Precision Cancer Therapy in Rare CancersRecruitingPhase 2Oslo University HospitalNCT06119789Written as Trametinib
See all 183 studies that test trametinib →
Given in every arm · 36 — trametinib is usual care beside what is tested
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as Trametinib
- A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaRecruitingPhase 1/2Therapeutic Advances in Childhood Leukemia ConsortiumNCT05849662Written as Trametinib
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid TumorsRecruitingPhase 1Vividion Therapeutics, Inc.NCT06804824Written as Trametinib
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as Trametinib
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2Bristol-Myers SquibbNCT05372354Written as Trametinib
- A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)RecruitingPhase 2Olivia Newton-John Cancer Research InstituteNCT05182931Written as Trametinib 2 MG
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT07468071Written as trametinib
- Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationTerminatedPhase 1/2Novartis PharmaceuticalsNCT05358249Written as trametinib
- Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02015117Written as Trametinib
- PDR001 Combination Therapy for Radioiodine-Refractory Thyroid CancerActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04544111Written as Trametinib
- Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaActive, not recruitingPhase 2Massachusetts General HospitalNCT03149029Written as Trametinib
- A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF AberrationActive, not recruitingPhase 1/2Pediatric Brain Tumor ConsortiumNCT04201457Written as Trametinib
- Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02152995Written as Trametinib
- Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT01989585Written as Trametinib
- Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01979523Written as Trametinib
- Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid TumorsTerminatedPhase 1Deciphera Pharmaceuticals, LLCNCT04892017Written as Trametinib
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid CancerCompletedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT03244956Written as Trametinib
- A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)Active, not recruitingPhase 3Erasca, Inc.NCT06346067Written as Trametinib
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingPhase 1Novartis PharmaceuticalsNCT03333343Written as trametinib
- A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid TumorsCompletedPhase 1C4 Therapeutics, Inc.NCT05668585Written as Trametinib
Showing 20 of 36.
As the comparator · 1 — what is tested is compared with trametinib
Codes
What other systems call trametinib · ClinicalTrials.gg INT005875
- MeSH (NLM) C560077trametinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 33E86K87QNTRAMETINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1425099Confirmed FDA, Wikidata
- Wikidata Q7833138trametinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77908TrametinibOne source FDA
- DrugBank DB08911One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C560077 | trametinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 33E86K87QN | TRAMETINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1425099 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7833138 | trametinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77908 | Trametinib | One source FDA |
| DrugBank | DB08911 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.